NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Egyptian Liver Journal

Table 3 Changes in the laboratory data of the study group

Variable	ALT	AST	PLT	Bilirubin	Fib-4	APRI
Baseline	44.86 ± 21.34	51.41 ± 22.95	195 ± 68	0.93 ± 0.40	2.42 ± 1.69	0.821 ± 0.08
4 weeks	25.19 ± 9.07	32.46 ± 11.93	196 ± 66	1.29 ± 0.69
Percent of change	− 43.84%	− 36.86%	0.41%	38.7%
p value	0.001*	0.001*	ns	0.001*
8 weeks	23.46 ± 9.33	27.64 ± 10.91	207 ± 74	1.26 ± 0.64
Percent of change	− 47.70%	− 46.23%	5.80%	35.48%
p value	0.001*	0.001*	ns	0.001*
12 weeks (EOT)	26.68 ± 7.96	29.03 ± 7.14	215 ± 52	0.98 ± 0.44
Percent of change	− 40.52%	− 43.54%	10.11%	5.37%
p value	0.001*	0.001*	0.05*	ns
12 weeks after EOT (SVR 12)	24.46 ± 7.63	29.53 ± 6.61	218 ± 64	0.77 ± 0.20	1.60 ± 0.61	0.407 ± 0.08
Percent of change	− 45.47%	− 42.55%	11.67%	− 17.2%	− 33.88%	− 50.42%
p value	0.001*	0.001*	0.05*	0.001*	0.001*	0.027*

Data were expressed as mean ± standard deviation
Percent of change = [(variable 12 weeks after EOT − variable at baseline)/variable at baseline] × 100
All p values compared the changes in the mean value of each parameter at a certain time in relation to the baseline, *Highly statistical significance
EOT endo of treatment, SVR12 sustained virological response with HCV RNA negative at 12 weeks after the end of therapy, ns not statistically significant